Navigation Links
Novartis Data Shows ACZ885 for Severe Gouty Arthritis Provided Better Pain Relief and Reduced Risk of New Attacks by Up to 68% vs. Steroid
Date:5/24/2011

EAST HANOVER, N.J., May 25, 2011 /PRNewswire/ -- Novartis announced today results of two pivotal Phase III trials in patients with severe gouty arthritis, showing that ACZ885 (canakinumab) provided superior pain relief and reduced the risk of suffering new attacks by up to 68% compared to an injectable steroid (triamcinolone acetonide, TA) used to treat gouty arthritis attacks(1,2). ACZ885 is an investigational fully human monoclonal antibody.

The studies involved more than 450 gouty arthritis patients for whom the standard anti-inflammatory therapies, non-steroidal anti-inflammatory drugs (NSAIDs) or colchicine, were inadequate or inappropriate(1,2). Results will be presented for the first time at the 2011 European League Against Rheumatism (EULAR) Congress in London.

"Patients describe gouty arthritis as agonizingly painful," said Naomi Schlesinger, MD, Associate Professor of Medicine, Chief, Division of Rheumatology, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson University Hospital. "This new research demonstrates that ACZ885, which inhibits interleukin-1 beta, effectively treated and extended the time to new gouty arthritis attacks, thus reducing new attacks in gouty arthritis patients for whom many standard therapies were inadequate or inappropriate."

Both trials used an internationally recognized pain scale to measure differences in pain 72 hours after treatment, and found ACZ885 reduced pain by an additional 11.4 millimeters (mm) (p=0.0005) in one study and 9.8 mm in the other (p=0.0018), compared to TA(1). ACZ885 also significantly reduced the risk of suffering a new gouty arthritis attack within three months compared to TA, by 55% in one study (p=0.0014) and 68% in the other (p<0.0001)(2).

Gouty arthritis, commonly referred to as gout, is a serious, chronic and progressive inflammatory disease that affects up to 8.3 million Americans(3,5). The most common form of inflammatory arthritis in adults,
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 22, 2014 Cyberonics, Inc. (NASDAQ: CYBX ... and management of epilepsy, today announced it will participate in ... Wednesday, January 14, 2015, in San Francisco ... Chief Executive Officer, will speak at 11:00 AM Pacific Time.  ... by clicking on the Investor Relations link on the Cyberonics ...
(Date:12/22/2014)... , Dec. 22, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation ... focused on discovering, developing and commercializing innovative therapies ... today issued the following open letter to shareholders ... Dr. Med. Sc. Dear RXi Shareholders, ... number of inaccurate statements posted on certain social ...
(Date:12/22/2014)... , Dec, 22, 2014  Eiger BioPharmaceuticals ... 2a study of lonafarnib in patients with chronic ... conducted at the National Institutes of Health (NIH) ... .  The double-blinded, randomized, placebo-controlled, dose ascending study ... daily and 200 mg twice daily for 28 ...
Breaking Medicine Technology:RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3
... from Mayo ClinicROCHESTER, Minn., March 23 Here ... Edge, Mayo Clinic,s research magazine. You may cite ... you wish. Reprinting is allowed with proper attribution. ... editorial policies permit: Visit http://discoverysedge.mayo.edu for ...
... Since 1993, when the PLCO trial was started, we have ... have others. The initial report of the results of this ... published last week in the New England Journal of Medicine ... The studies offer conflicting evidence about the possibility of a ...
Cached Medicine Technology:Discovery's Edge Spring Issue - http://discoverysedge.mayo.edu 2A Joint Statement From America's Prostate Cancer Advocacy, Education, and Support Organizations 2A Joint Statement From America's Prostate Cancer Advocacy, Education, and Support Organizations 3
(Date:12/26/2014)... (PRWEB) December 26, 2014 Pentec Health, ... in the state of Pennsylvania for 2014. The awards ... statewide programs of its kind in the country. The ... the Pennsylvania Department of Community and Economic Development, the ... Management and the Central Penn Business Journal. ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... 2014 Recently, iFitDress.com, the popular online supplier ... announced its new selection of black one-shoulder cocktail dresses ... now; they are available at discounted prices, up to 70% ... will last for three weeks only. You know, we have ... are interested in our new items can visit our website ...
(Date:12/25/2014)... December 25, 2014 Helen Harris’ RP ... Woodland Hills, California after an 8 year battle with ... Christmas Eve evening in her home in Woodland Hills ... breast cancer. , As the founder ... years, she pioneered and championed many of today's greatest ...
(Date:12/25/2014)... THURSDAY, Dec. 25, 2014 (HealthDay News) -- Overeating is common ... you eat in moderation, an expert says. "Don,t arrive ... up calories if you know you,ll be attending a party, ... Jill Ashbey-Pejoves, lead dietitian at Northern Westchester Hospital in Mount ... better to eat healthy during the day and even to ...
Breaking Medicine News(10 mins):Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4
... published in the April 25 early online edition of ... researchers at the University of California, San Diego ... and colleagues report a game-changing advance in stem cell ... cells from human embryonic stem cells (hESCs) that can ...
... pancreatitis that gets results much faster than existing tests has ... Austin. The sensor, which could be produced for as ... light, aluminum foil, gelatin, milk protein and a few other ... damage from acute pancreatitis, which is a sudden inflammation of ...
... , MONDAY, April 25 (HealthDay News) -- Most Americans ... many don,t understand the need to limit consumption, finds an ... mistakenly believe that sea salt is a low-sodium alternative to ... assess awareness about how wine and sodium affect heart health. ...
... Queen,s University have found a strong association between computer ... behaviours (MRB), including illicit drug use, drunkenness and unprotected ... theory, which suggests that seeing people engaged in a ... lead researcher Valerie Carson, a doctoral candidate in School ...
... given the slip by the protein fibulin-5 ... affects almost 50% of women over the age of ... a woman,s pelvic organs weaken such that the pelvic ... vagina. For many affected women, treatment involves surgery. Defining ...
... A new study suggests that it,s possible to predict future ... behavior. Bipolar people suffer from extreme mood swings ... deep depression. In the new study, researchers from the Universities ... bipolar patients for a month, studying how they think and ...
Cached Medicine News:Health News:Scientists create stable, self-renewing neural stem cells 2Health News:Self-powered, blood-activated sensor detects pancreatitis quickly and cheaply 2Health News:Many Americans Ill-Informed About Red Wine, Sea Salt: Survey 2Health News:JCI table of contents: April 25, 2011 2Health News:JCI table of contents: April 25, 2011 3Health News:JCI table of contents: April 25, 2011 4Health News:JCI table of contents: April 25, 2011 5Health News:JCI table of contents: April 25, 2011 6Health News:It May Be Possible to Predict Bipolar Mood Swings: Study 2
Used to obtain biopsy specimens from pathological lesions in the ureter, renal pelvis, infundibula, or calyces. Supplied sterile in peel-open packages. Intended for one-time use....
Used to obtain tissue biopsy under direct vision. Cup Biopsy Forceps are designed for use through rigid or flexible endoscopes. Supplied sterile in peel-open packages. Intended for one-time use....
... Series 1000 Power Instrument System is a ... and convenience with modular and unitized handpieces., ... for use with 1025 Power Console. Accepts ... Also available without hand throttle (#1000E) for ...
... Micro Drill, without hand throttle, ... torque. Built-in medium bur guard ... (#1100-006) bur guards are also ... foot throttle (#6401-000), can also ...
Medicine Products: